Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial
Noorazrul Yahya, Martin A Ebert, Max Bulsara, Annette Haworth, Angel Kennedy, David J Joseph, Jim W Denham
Radiotherapy and Oncology | ELSEVIER IRELAND LTD | Published : 2015
Awarded by Diagnostics and Technology Branch of the Australian Government Department of Health and Ageing
Awarded by National Health and Medical Research Council - Australia
We acknowledge funding from Cancer Australia and the Diagnostics and Technology Branch of the Australian Government Department of Health and Ageing (Grant 501106), the National Health and Medical Research Council - Australia (Grants 300705, 455521, 1006447), the Hunter Medical Research Institute, the Health Research Council (New Zealand), the University of Newcastle and the Calvary Mater Newcastle, Abbott Laboratories, Novartis Pharmaceuticals. We gratefully acknowledge the support of the participating RADAR centres, Chantelle Wilcox and the Trans-Tasman Radiation Oncology Group. We are grateful to Michelle Krawiec and Sharon Richardson for delineating bladder structures on trial datasets, and Sarah Gulliford for helpful comments.